Print Page     Close Window     

SEC Filings

10-K
SERES THERAPEUTICS, INC. filed this Form 10-K on 03/06/2019
Entire Document
 

 

SERES THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(amounts in thousands, except share and per share data)

 

 

5.

Property and Equipment, Net

Property and equipment, net consisted of the following:

 

 

 

December 31,

2018

 

 

December 31,

2017

 

Laboratory equipment

 

$

14,695

 

 

$

13,181

 

Computer equipment

 

 

2,864

 

 

 

2,832

 

Furniture and office equipment

 

 

1,033

 

 

 

1,033

 

Leasehold improvements

 

 

27,977

 

 

 

27,963

 

Construction in progress

 

 

26

 

 

 

361

 

 

 

 

46,595

 

 

 

45,370

 

Less: Accumulated depreciation and amortization

 

 

(20,301

)

 

 

(12,439

)

 

 

$

26,294

 

 

$

32,931

 

 

Depreciation and amortization expense was $7,862, $7,259 and $4,205 for the years ended December 31, 2018, 2017 and 2016, respectively.

 

 

6.

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:

 

 

 

December 31,

2018

 

 

December 31,

2017

 

Development and clinical manufacturing costs

 

$

7,046

 

 

$

3,910

 

Payroll and payroll-related costs

 

 

5,020

 

 

 

4,962

 

Facility and other

 

 

3,141

 

 

 

3,641

 

 

 

$

15,207

 

 

$

12,513

 

 

 

7.

Convertible Preferred Stock

On July 1, 2015, in connection with the closing of the initial public offering of the Company’s common stock (“IPO”), the Company effected its Restated Certificate of Incorporation, which authorizes the Company to issue 10,000,000 shares of preferred stock, $0.001 par value per share.

 

 

8.

Stockholders’ Equity Common Stock

On July 1, 2015, in connection with the closing of the IPO, the Company effected its Restated Certificate of Incorporation, which authorizes the Company to issue 200,000,000 shares of common stock, $0.001 par value per share.

2012 Stock Incentive Plan

The Company’s 2012 Stock Incentive Plan, as amended, (the “2012 Plan”) provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors and consultants of the Company. The 2012 Plan is administered by the board of directors, or at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of stock option may not be greater than ten years. The Company generally granted stock-based awards with service conditions only (“service-based” awards).

F-18



© Seres Therapeutics. All Rights Reserved.